New Israeli Fund Targets $40 Million for Mental Health and Longevity

A new Israeli venture fund is seeking $40 million to back startups working on mental health and longevity, CTech reports.

The figure marks the vehicle's fundraising target, not a closed pool. The report doesn't name the fund's general partners or disclose anchor investors. It also doesn't specify a first close date or a timeline for deploying capital.

Israel's startup ecosystem has produced a steady stream of health-tech vehicles in recent years, and the new fund's two chosen themes — mental health and longevity — sit among the sector's most active fundraising categories.

What do the two target sectors cover?

Mental health investing covers digital therapeutics, psychiatric drug development and workplace-wellness platforms. Longevity investing spans biotech companies targeting the biology of aging, age-related disease and lifespan extension.

CTech's report frames the $40 million vehicle as a dedicated play on both categories, an unusually tight mandate for an Israeli fund of this size. Most local health-tech funds cast wider nets across medical devices, diagnostics and digital health.

How large is a $40 million fund in this market?

At $40 million, the fund fits the seed-to-Series-A niche. That scale typically means checks of $1 million to $5 million per deal, though the report doesn't confirm check sizes or portfolio construction targets.

The target also signals limited-partner appetite for single-theme health funds remains intact, even after two years of compressed biotech valuations across global markets.

What comes next?

Expect a formal first-close announcement, likely with named partners and anchor LPs, before the fund begins announcing deals. Until then, the $40 million target stands as the market signal: Israeli investors still see durable returns in the mind and the aging body.